![Jean-Jacques Kiladjian: The new findings of Proud-Continuation PV randomized trial](https://oncodaily.com/pub/uploads/2024/06/kiladjian-e1718469389609-1280x721.jpg)
Photo taken from
Gonzalo Carreño Gómez-Tarragona/X
Jun 17, 2024, 01:15
Jean-Jacques Kiladjian: The new findings of Proud-Continuation PV randomized trial
Jean-Jacques Kiladjian, Professor of Clinical Pharmacology at Paris Diderot University, shared a post on X:
“Don’t miss the new findings of Proud-Continuation PV randomized trial showing the correlation between JAK2 mutation reduction with ropeginterferon alpha 2b and better event-free survival!
Molecular response is a meaningful goal of therapy in PV.”
Source: Jean-Jacques Kiladjian/X